Drug Trial Radar · NCT06881823
Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC
Last checked: Nov 20, 2026Latest source record: Dec 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jun 29, 2026
Primary completion
Mar 31, 2030
Study completion Jun 1, 2033
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Mar 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to learn more about the effects of AAA602 and AAA802 in men with prostate-specific membrane antigen (PSMA) positive high-risk localized prostate cancer (HRLPC) before surgery to remove the prostate and lymph nodes present in the pelvis area. Lymph nodes are small structures near the prostate that help fight infections. These lymph nodes are removed during surgery because they are a site the disease can spread to.
Conditions
- Prostate Cancer
Interventions
AAA602Drug
\[177\]Lu-PSMA-R2 Radiopharmaceutical solution for injection/infusion.
AAA802Drug
\[225\]Actinium-PSMA-R2 radiopharmaceutical solution for injection/infusion
Gallium (68Ga) gozetotideDrug
Radioligand Imaging compound. Provided as a kit for radiopharmaceutical preparation of gallium (68Ga) gozetotide. Solution for injection.
Piflufolastat (18F)Drug
Radioligand Imaging compound. Provided as a ready-to-use radiopharmaceutical.
Flotufolastat F 18Drug
Radioligand Imaging compound. Provided as a ready to use radiopharamceutical.
18F-PSMA-1007Drug
Radioligand Imaging compound. Provided as a ready to use radiopharmaceutical.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with dose-limiting toxicities (DLTs) (Phase l)Time frame: At the end of cycle 1 (each cycle is maximum 6 weeks)
- Biochemical recurrence free survival (BFS) (Phase ll)Time frame: From the date of surgery until the date of confirmed biochemical recurrence or death due to any cause, whichever occurs first assessed to approximately 60 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.